Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=27409915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE46197(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/389,860external-prioritypatent/US20010051616A1/en
Application filed by Merck & Co IncfiledCriticalMerck & Co Inc
Publication of PE46197A1publicationCriticalpatent/PE46197A1/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Peptides Or Proteins
(AREA)
Abstract
QUE APLICADO EN MUJERES OSTEROPOROSICAS, COMPRENDE ADMINISTRAR ORALMENTE UNA CANTIDAD DIARIA DE 5 mg A 20 mg DE ALENDRONATO O UNA SAL FARMACEUTICAMENTE ACEPTABLE POR UN PERIODO DE AL MENOS TRES ANOS; CUANDO SE ADMINISTRA ORALMENTE ANTES DE LA FRACTURA EN UNA DOSIS DIARIA Y POR UN PERIODO SIMILAR A LO ANTERIOR EL ALENDRONATO PUEDE REDUCIR LA SEVERIDAD DE LA FRACTURA; ADEMAS PUEDE REDUCIR LA DEFORMACION COLUMNAR Y LA PERDIDA DE ALTURA EN MUJERES OSTEOPOROSICAS MEDIANTE ADMINISTRACION ORAL
PE00009596A1995-02-171996-02-12Metodo para disminuir el riesgo de fracturas vertebrales y no-vertebrales
PE46197A1
(es)
Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas